During the past decade, The Mark H Zangmeister Center conducted 182 clinical trials. In the 10-year time frame, 182 clinical trials started and 110 clinical trials were completed, i.e. on average, 60.4% percent of trials that started reached the finish line to date. In the past 5 years, 80 clinical trials started and 78 clinical trials were completed. i.e. 97.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Mark H Zangmeister Center" #1 sponsor was "National Cancer Institute (NCI)" with 102 trials, followed by "SWOG Cancer Research Network" with 40 trials sponsored, "Alliance for Clinical Trials in Oncology" with 29 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 13 trials sponsored and "NRG Oncology" with 13 trials sponsored. Other sponsors include 77 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Mark H Zangmeister Center" #1 collaborator was "National Cancer Institute (NCI)" with 116 trials as a collaborator, "NRG Oncology" with 36 trials as a collaborator, "Canadian Cancer Trials Group" with 10 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator. Other collaborators include 53 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "The Mark H Zangmeister Center" are "Recurrent Ovarian Carcinoma" (13 trials), "Breast Cancer" (11 trials), "Recurrent Fallopian Tube Carcinoma" (10 trials), "Recurrent Squamous Cell Lung Carcinoma" (10 trials) and "Stage IV Lung Cancer AJCC v8" (10 trials). Many other conditions were trialed in "The Mark H Zangmeister Center" in a lesser frequency.

Most popular intervention types in "The Mark H Zangmeister Center" are "Drug" (220 trials), "Other" (146 trials), "Biological" (85 trials), "Procedure" (56 trials) and "Radiation" (31 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (69 trials), "Quality-of-Life Assessment" (67 trials), "Paclitaxel" (42 trials), "Carboplatin" (41 trials) and "Questionnaire Administration" (40 trials). Other intervention names were less common.

The vast majority of trials in "The Mark H Zangmeister Center" are 205 trials for "All" genders, 63 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "The Mark H Zangmeister Center". undefined are not yet recruiting, 70 are recruiting, 123 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 61 completed trials in The Mark H Zangmeister Center, 4 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in The Mark H Zangmeister Center, 9 "Phase 1" clinical trials were conducted, 121 "Phase 2" clinical trials and 144 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 7 trials that are defined as “Not Applicable".